Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of ISB 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK) / pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed / refractory multiple myeloma.
Multiple Myeloma
I
Mohan, Sanjay
NCT03309111
VICCHEMP17111

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: